"Sarcopenia" originates from Greek and literally means "lack of flesh." In the literature, the term is widely used as a synonym of low muscle mass; however, the international consensus guidelines for this condition (European Working Group on Sarcopenia in Older People/Foundation for the National Institutes of Health) are clear about its definition. Both groups recommend using the presence of low skeletal muscle mass and low muscle function (strength or performance) for the diagnosis of sarcopenia.[@b1-gnl-13-005]

Sarcopenia is a more complex condition than can be described by either single factor.[@b1-gnl-13-005] There are multiple factors that may contribute to sarcopenia in patients with nonalcoholic fatty liver disease (NAFLD). The causes that are responsible for sarcopenia in NAFLD patients include increased insulin resistance, changes in levels of myokines such as growth differentiation factor 15 (GDF-15),[@b2-gnl-13-005] elevated chronic inflammation markers, and lower vitamin D levels.

When assessing sarcopenia, muscle mass is usually normalized to weight (kg) or height squared (m^2^). With dual-energy X-ray absorptiometry (DEXA), which is one of the recognized gold standards in clinical assessment of sarcopenia (the other being computed tomography/magnetic resonance imaging), the most recent muscle mass index, validated in multiethnic populations, is determined as follows: appendicular skeletal muscle mass (kg) divided by body mass index (kg/m^2^).[@b3-gnl-13-005]

Several study groups have investigated an association between muscle mass or sarcopenia and NAFLD in cross-sectional settings.[@b4-gnl-13-005]--[@b6-gnl-13-005] Moreover, it has recently been reported that reduced skeletal muscle mass increases the risk of the onset of NAFLD[@b4-gnl-13-005],[@b6-gnl-13-005],[@b7-gnl-13-005] as well as the risk of liver fibrosis.[@b7-gnl-13-005] Shida *et al*.[@b8-gnl-13-005] have explored whether a reduction in skeletal muscle mass and an increase in visceral fat mass are associated with the risk of the onset of NAFLD and serve as important risk factors involved in the progression of liver fibrosis. Recently, Kim *et al*.[@b9-gnl-13-005] have observed that an increase in relative skeletal muscle mass over time may be beneficial for preventing NAFLD development or resolving NAFLD in a dose-dependent manner, independent of the baseline skeletal muscle index.

In the current issue, Lee *et al*.[@b10-gnl-13-005] have found that a progressive increase in the fat mass and a loss of skeletal muscle mass with aging were significantly associated with incident NAFLD in the general population. The authors assessed aging-related changes in the body composition over a 10-year period in a relatively large population. In particular, they showed that a decreased muscle mass was significantly associated with incident NAFLD in nonobese but not in obese subjects after adjustment for various metabolic risk factors.

The skeletal muscle mass was measured by means of bio-electrical impedance analysis, although it was not as precise as direct measures of muscle mass. In subgroup analyses, the absolute change in appendicular skeletal muscle mass was significantly associated with incident NAFLD, particularly in the non-obese and female subgroups. These results are notable because nonobese NAFLD is more frequently found in Asian countries than in Western regions.

Meanwhile, important nutritional and body compositional variables, confounding or mediating the associations among obesity, sarcopenia, and NAFLD, such as the vitamin D level and visceral adiposity, were not analyzed in the current study. In addition, the data should have been adjusted for the physical activity level, which is related to the axial muscle mass, since unlike the core muscle mass, the axial muscle mass is affected by physical activity. Moreover, the study only presented odds ratios but not hazard ratios for incident NAFLD, without any data on regressed NAFLD, although the researchers followed the study population for 10 years. Therefore, it was difficult to accurately estimate the incidence of NAFLD or predict the regression of NAFLD during the study period.

Despite these limitations, it was a well-designed, retrospective, single-institution study including a large community-based population. It unveiled the association of the absolute change in skeletal muscle mass with incident NAFLD by using longitudinal cohort data. Additionally, this study showed a stronger association between decreasing skeletal muscle mass and incident NAFLD in nonobese subjects, highlighting that sarcopenia as well as visceral adiposity, dietary preferences (e.g., a high-fructose diet), and genetic polymorphisms are well-known metabolic or genetic risk factors for nonobese or lean NAFLD. However, further studies involving detailed histological assessment and adjunct evaluation of muscle quality are warranted to clarify the causal relationship between sarcopenia or sarcopenic obesity and NAFLD development or progression.
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